ArticleJournal of the National Cancer Institute2015
Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.The Cochrane database of systematic reviews · 2021Pooled it
- Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.Journal of the National Cancer Institute · 2026Trial
- Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Change in mammographic density as a potential predictor of cancer recurrence after breast conservation surgery and adjuvant endocrine therapy: results of the MEDICI study.Breast cancer research : BCR · 2026Article
- Comparison of Visual and Quantra Software Mammographic Density Assessment According to BI-RADSJournal of imaging · 2024Article
- The Relationship Between Breast Density and Breast Cancer Surgical Outcomes: A Systematic Review.Cureus · 2024Review
- Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence.Cancer medicine · 2024Article
- Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer.Korean journal of radiology · 2023Article
- Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study.Breast cancer research : BCR · 2023Article
- Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy.NPJ breast cancer · 2023Article
- Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.JNCI cancer spectrum · 2022Article
- Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography.Journal of clinical medicine · 2022Article
- Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.Breast cancer research and treatment · 2021Article
- Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.Breast (Edinburgh, Scotland) · 2020Article
- Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.Breast cancer research : BCR · 2020Article
- Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.Breast cancer research : BCR · 2020Article
- Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement.European radiology · 2020Article
- Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients.Journal of clinical medicine · 2019Article
- Prevalence of Women with Dense Breasts in Korea: Results from a Nationwide Cross-sectional Study.Cancer research and treatment · 2019Article
- A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.Breast cancer research and treatment · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundA prior analysis of postmenopausal breast cancer patients linked a decline in mammographic density (MD) following the initiation of tamoxifen treatment with improved survival, but excluded premenopausal women, for whom tamoxifen is the primary anti-endocrine therapy. Therefore, we evaluated change in MD after tamoxifen and breast cancer death among patients age 32 to 87 years.
methodsThis case-control study included 349 estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen at Kaiser Permanente Northwest (1990-2008): 97 who died from breast cancer (case patients) and 252 who did not (control patients), matched on age and year at diagnosis and disease stage. Percent MD in the unaffected breast was measured at baseline (mean six months before tamoxifen initiation) and follow-up (mean 12 months after initiation). Associations between change in MD and breast cancer death were estimated using conditional logistic regression.
resultsPatients in the highest tertile of MD decline had a lower risk of breast cancer death when compared with women in the lowest tertile (odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.22 to 0.88); results were similar after adjustment for baseline MD (OR = 0.49, 95% CI = 0.23 to 1.02). Reductions in death were observed only among patients in the middle and upper tertiles of baseline MD. Associations did not differ by age, tamoxifen use duration, estrogen and/or progestin use, body mass index, or receipt of chemotherapy or radiotherapy.
conclusionThese data suggest that younger and older ER-positive breast cancer patients who experience large reductions in MD following tamoxifen initiation have an improved prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.